Related Experiment Video

Updated: Aug 25, 2026

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
10:12

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Published on: September 11, 2019

Challenges in the management of HIV and hepatitis C virus co-infection

Winston Lee1, Douglas Dieterich

  • 1Mount Sinai Medical Center, 1 Gustave L. Levy Place, Box 1118, New York, NY 10029, USA.

Drugs
|March 18, 2004
PubMed

Insights

Hepatitis C virus (HCV) co-infection with HIV accelerates liver damage. Treatment with pegylated interferon and ribavirin is tolerated but less effective, requiring close monitoring due to potential severe toxicity.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) significantly increases morbidity and mortality in HIV-infected individuals, especially since the advent of highly active antiretroviral therapy (HAART).
  • HIV infection negatively impacts the natural course of HCV, leading to accelerated liver damage.
  • The high prevalence of HIV-HCV co-infection necessitates effective management strategies for chronic HCV.

Purpose of the Study:

  • To evaluate the treatment of chronic Hepatitis C virus infection in patients co-infected with Human Immunodeficiency Virus.
  • To assess the efficacy and tolerability of pegylated interferon and ribavirin in this co-infected population.
  • To highlight special considerations for HAART in the context of HCV infection.

Main Methods:

  • Review of existing studies on pegylated interferon and ribavirin treatment in HIV-HCV co-infected patients.
  • Analysis of the impact of HAART on HCV-infected individuals.
  • Monitoring of treatment-related toxicity, particularly hepatotoxicity.

Main Results:

  • Pegylated interferon and ribavirin treatment appears to be generally well-tolerated in co-infected patients.
  • The effectiveness of pegylated interferon and ribavirin may be reduced in the HIV-HCV co-infected group compared to HCV-monoinfected individuals.
  • HAART in the presence of HCV infection is associated with an increased incidence of hepatotoxicity.

Conclusions:

  • Treatment of chronic HCV in HIV-co-infected patients is crucial due to accelerated liver damage.
  • Current therapeutic options for HCV in HIV-co-infected individuals have limitations in effectiveness and carry risks of severe toxicity.
  • Close monitoring is essential for managing HIV-HCV co-infected patients undergoing treatment.

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...